Clinical Trial Update: ATOM_local Ablative Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for atom local ablative therapy in non-small cell lung cancer with activating EGFR mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ATOM_local Ablative Therapy

Snippet

Sponsor: Chinese University of Hong Kong | Conditions: NSCLC, Activating EGFR Mutation | Phase 2 | Status: COMPLETED